Chapter 4 · The Score That Changed Everything

The hepatologist's office was sterile in a way that made Mark's shoulders tense. Bright overhead lights. Off-white walls. The faint smell of Lysol and hand sanitizer. He'd been waiting for twelve minutes — not long, but long enough to read through an outdated magazine about Mediterranean cooking and notice that his palms were sweating.

Dr. Anh Nguyen came in with his chart in her hands, scanning it as she walked. She was younger than Mark expected, maybe early fifties, with sharp eyes that seemed to inventory him in the time it took to sit down.

"I've reviewed your ultrasound, your lab work, and your clinical history," she said, not looking up. "Let me walk you through what we're seeing."

Mark braced himself. He'd spent the previous week in a state of suspended tension, caught between the hope Priya had offered at 2 AM — even people with fibrosis get better — and the catastrophe he'd been constructing in his own head since the diagnosis. He didn't know which version of reality he was about to receive.

Dr. Nguyen pulled up an image on her computer. His ultrasound, the liver rendered in grayscale. It looked like a blob. Mark had no idea what he was looking at, but he stared at it anyway, the way you stare at an X-ray of your own bones — searching for meaning in a picture that requires years of training to interpret.

"Your liver shows moderate hepatic steatosis," she said. "That's consistent with Stage 1 NAFLD — or MASLD, as we call it now. No signs of cirrhosis. No significant fibrosis on the ultrasound." She paused. "The good news is, we're catching this early."

Mark nodded, trying to feel the relief he knew he was supposed to feel. But the word early had a shadow behind it. Early implied a later. Early implied a progression that hadn't happened yet but could.

"But," she continued, "ultrasound is a blunt instrument. It shows us the fat, but it can't precisely assess scarring. To really evaluate your fibrosis risk, I use a calculation called FIB-4." She looked at him. "Have you heard of it?"

He hadn't.

Dr. Nguyen turned to her computer and pulled up a simple spreadsheet. Four input boxes: Age. AST. ALT. Platelets.

"FIB-4 is a noninvasive score that uses your basic lab values to estimate whether you have advanced fibrosis. It's surprisingly accurate for screening — and it means we can avoid a liver biopsy in most cases." She started typing. "Let me plug in your numbers."

Age: 34. AST: 52. ALT: 78. Platelets: 235,000.

She hit enter. A number appeared on the screen: 0.68

Dr. Nguyen smiled. It was the first time Mark had seen her smile.

"0.68," she repeated. "That's excellent. That puts you in the lowest risk category. A FIB-4 below 1.30 means there's a 95% or higher chance that you do not have advanced fibrosis." She turned the monitor slightly toward him. "Your liver isn't scarred, Mark. We caught this early."

Something released in his chest. Not the tension itself — that had been building for weeks — but the scaffolding that held it up. The structure of catastrophe he'd been assembling since that first appointment with Dr. Kim. It didn't collapse all at once. It just loosened, like a fist unclenching.

0.68. Not a number that meant disaster. A number that meant he still had time.

"What if it gets worse?" he asked. "What if I don't make changes and it starts climbing?"

"Then we recheck it in eight weeks and make decisions based on the trend. But Mark —" she leaned forward slightly, "— you're 34 years old with a FIB-4 of 0.68. Metabolic dysfunction is modifiable. Weight loss is achievable. Intermittent fasting has strong evidence behind it. You have leverage here."

She wrote a number on a piece of paper and slid it across the desk: 1.30

"If your FIB-4 ever climbs above 1.30, we'd have a serious conversation about escalating treatment — possibly medications like pioglitazone or GLP-1 agonists. Between 1.30 and 2.67 is a gray zone where we'd order more imaging. Above 2.67, we assume advanced fibrosis and act accordingly." She tapped the paper. "But right now, you're safely below 1.30. You're in the window where lifestyle change works."

Mark folded the piece of paper and put it in his wallet. He wasn't sure why. It wasn't a prescription or a business card. It was a threshold — a line drawn between the version of his future where things stayed manageable and the version where they didn't. He wanted to keep it close.

As he drove home, he kept replaying the moment Dr. Nguyen had smiled. Not the polished smile of someone delivering good news to a patient, but the genuine expression of someone who understood what she'd just given him: the knowledge that his liver wasn't scarred, and the time to prevent it from becoming scarred.

The FIB-4 score — 0.68 — became the number that made everything concrete. Not a feeling. Not a doctor's reassurance. A calculation, a ratio of his own biology, that proved mathematically he was in the early stages of a reversible disease. And if it was reversible at a score like that, then every choice he made in the next weeks and months carried real weight. Not shame-weight. Empowerment-weight.

That night, Mark opened the app and scrolled to the fibrosis risk section. He typed in his FIB-4: 0.68. The screen displayed a green indicator — LOW RISK — and a visualization of the three tiers, with his score positioned safely in the green zone on the left. To the right, the yellow and red zones loomed like weather on a distant horizon.

The app listed lifestyle interventions for FIB-4 improvement: intermittent fasting protocols, exercise targets, weight loss benchmarks, expected enzyme improvements at each milestone. For the first time, his diagnosis didn't feel like a death sentence or a medical abstraction. It felt like a game where the score was visible, the goal was clear, and the path forward was something he could actually walk.

He set a reminder: recheck in eight weeks. That felt like a real timeline. Not an abstract future. A deadline he could work toward.